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Abstract
Background: Identification of islet β cell death prior to the onset of type 1 diabetes (T1D) or type 2 diabetes (T2D)
might allow for interventions to protect β cells and reduce diabetes risk. Circulating unmethylated DNA fragments
arising from the human INS gene have been proposed as biomarkers of β cell death, but this gene alone may not
be sufficiently specific to report β cell death.
Results: To identify new candidate genes whose CpG sites may show greater specificity for β cells, we performed
unbiased DNA methylation analysis using the Infinium HumanMethylation 450 array on 64 human islet preparations
and 27 non-islet human tissues. For verification of array results, bisulfite DNA sequencing of human β cells and 11
non-β cell tissues was performed on 5 of the top 10 CpG sites that were found to be differentially methylated. We
identified the CHTOP gene as a candidate whose CpGs show a greater frequency of unmethylation in human islets.
A digital PCR strategy was used to determine the methylation pattern of CHTOP and INS CpG sites in primary
human tissues. Although both INS and CHTOP contained unmethylated CpG sites in non-islet tissues, they occurred
in a non-overlapping pattern. Based on Naïve Bayes classifier analysis, the two genes together report 100%
specificity for islet damage. Digital PCR was then performed on cell-free DNA from serum from human subjects.
Compared to healthy controls (N = 10), differentially methylated CHTOP and INS levels were higher in youth with
new onset T1D (N = 43) and, unexpectedly, in healthy autoantibody-negative youth who have first-degree relatives
with T1D (N = 23). When tested in lean (N = 32) and obese (N = 118) youth, increased levels of unmethylated INS
and CHTOP were observed in obese individuals.
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Conclusion: Our data suggest that concurrent measurement of circulating unmethylated INS and CHTOP has the
potential to detect islet death in youth at risk for both T1D and T2D. Our data also support the use of multiple
parameters to increase the confidence of detecting islet damage in individuals at risk for developing diabetes.
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Background
Diabetes mellitus is a multifactorial disease that occurs
following the dysfunction or death of insulin-producing β
cells in the pancreas. Globally, there is an alarming in-
crease in the incidence of type 1 diabetes (T1D) and type
2 diabetes (T2D), and it is estimated that 425 million indi-
viduals are afflicted with diabetes worldwide [1]. Trad-
itionally, both major forms of diabetes have been viewed
as distinct: T1D develops as a result of selective destruc-
tion of pancreatic β cells by the immune system, while
T2D develops secondary to insufficient insulin secretion
in the context of insulin resistance in peripheral tissues. In
both forms, clinical manifestations of disease occur only
after substantial loss of functional β cell mass, and applica-
tion of therapeutic interventions at this time point has at
best had very limited success in restoring β cell mass and
function. Results from our group and others have demon-
strated that activation of stress pathways within β cells oc-
curs during the very early phases of both T1D and T2D,
resulting in β cell death and/or dysfunction [2–4]; there-
fore, the noninvasive or minimally invasive detection of β
cell death has the potential to serve as an early biomarker
of future clinical disease and for monitoring the impact of
novel therapeutic interventions.
Recently, we and others have proposed the measure-
ment of circulating unmethylated DNA encoding
preproinsulin (INS) as a biomarker for β cell damage
[5–8]. Given the increased frequency of unmethylated
INS CpG sites in β cells, the ratio of unmethylated-to-
methylated INS DNA released into the circulation
upon cell death is considered a reflection of β cell
death. However, we recently developed a multiplex
PCR-based assay using a more precise droplet digital
PCR (dPCR) technique to directly quantitate differen-
tially methylated DNA species, and discovered that
subjects with new onset (T1D) display significantly
elevated levels of both unmethylated and methylated
INS DNA compared to controls [6, 9]. Notably, al-
though β cells have been identified as containing
predominantly unmethylated INS DNA, other cell
types also contain varying, but lower, levels of
unmethylated INS [7]. Therefore, the appearance of
circulating unmethylated INS does not exclusively
report on β cell death, and more rigorous or comple-
mentary biomarkers are needed.
In an effort to address the current limitations of differ-
entially methylated INS as a biomarker for β cell dam-
age, we hypothesized that other differentially methylated
genes would show either greater specificity for β cells or
could be used as complementary biomarkers to increase
β cell specificity. To test this hypothesis, we utilized an
unbiased approach leveraging the Infinium Human-
Methylation 450 array to identify new differentially
methylated CpG targets in human islets. We identified
an intragenic CpG site in the gene encoding chromatin
target of PRMT1 (CHTOP) that exhibits complementary
tissue specificity to INS and may be used to increase
confidence of detecting islet damage in youth with pre-
diabetes and diabetes.
Results
Identification of differentially methylated genes from
isolated human islet DNA
To identify genes that exhibit differential methylation in
primary human islets, we assessed DNA methylation by
Infinium® 450 K array datasets in 64 human islet prepa-
rations and leveraged data from 27 publicly available
non-islet human tissues (see the “Methods” section).
The Infinium® 450 K array covers > 480,000 CpG sites
and targets ~ 96% of CpG islands in human genome
[10]. Our overall analytic and experimental approach is
shown in the flow diagram in Supplemental Fig. S1. In-
formatics analysis of these datasets identified 2534 hypo-
methylated CpG sites and 3667 hypermethylated CpG
sites in human islets vs. non-islet tissues. The 10 most
highly differentially methylated CpG sites are shown in
Fig. 1. To verify the methylation status of the identified
genes, we performed PCR amplification of a 0.5-kb
segment surrounding 5 of the differentially methylated
CpG sites (chr12, 49759545; chr2, 189064557; chr8,
126649807; chr3, 1355702110; chr1, 153610672) using
bisulfite-treated DNA from fluorescence-sorted primary
human β cells (using Newport Green selection, see
Supplemental Fig. S2) from 3 different islet preparations,
the EndoC-βH1 human β cell-derived line [11] and 11
non-islet human tissues (the remaining 5 differentially
methylated CpG sites were not easily amenable to PCR
amplification and therefore not pursued further). Prod-
ucts were pooled and deep-sequenced and methylation
status of CpG sites was determined. Out of the top 5
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differentially methylated CpG sites, CpGs in CHTOP
(C1orf77) gene, which encodes chromatin target of
PRMT1, were found to be substantially differentially
methylated in primary sorted human β cells (48–99%
hypomethylated) compared to non-islet tissues samples
(Fig. 2 a and b). Notable exceptions, however, included
heart and skeletal muscle, each of which displayed at
least 50% hypomethylation at CpG sites across the
CHTOP gene. Surprisingly, CHTOP CpGs were not
hypomethylated in EndoC-βH1 cells (Fig. 2b), consistent
with an epigenetic divergence between an embryonic cell
line and mature β cells. To determine the stability of
CpG site hypomethylation to pro-inflammatory cyto-
kines (inflammatory messengers implicated in diabetes),
β cells were treated with IFN-γ and IL-1β for 24 h, and
then sequenced. The hypomethylation of CpG sites
within the CHTOP gene was not altered by cytokine
treatment (Fig. 2b).
Next, we developed TaqManTM probe-based PCR assays
to quantitatively measure differential methylation of the
CHTOP gene at site chr1, 153610817 (a.k.a. CHTOP-817)
using droplet digital PCR (dPCR), a technique that allows
for absolute quantitation of DNA copy numbers [12].
CHTOP-817 was selected based on optimal primer and
probe characteristics, as determined by the software algo-
rithm at the manufacturer’s website. To determine the
sensitivity and linearity of the CHTOP-817 assay, we first
mixed varying proportions of the cloned unmethylated
and methylated plasmids of the CHTOP gene. Figure 3 a
shows the gating strategy in 2-dimensional droplet dPCR
plots to detect droplets containing unmethylated and
methylated CHTOP-817. For verification of linearity and
ability to distinguish simultaneous mixtures of the DNA
species, mixtures of plasmids at varying ratios were sub-
jected to droplet dPCR as shown in Fig. 3b. To verify lin-
earity of the assay across a range of concentrations seen in
circulation, we next spiked various amounts of genomic
DNA from human islets into serum from a healthy human
donor, as shown in Fig. 3 c and d. Linearity was estab-
lished for both methylated and unmethylated CHTOP-817
and preserved below the 2 copies/microliter range (though
sensitivity of the methylated CHTOP-817 assay appeared
relatively less linear and less sensitive in this range). Using
the linearity validation strategy in Fig. 3 c and d, we cre-
ated an additional two primer/probe combinations for the
CHTOP gene to interrogate two other CpG sites (chr1,
153610800 and chr1, 153610824, a.k.a. CHTOP-800 and
CHTOP-824, respectively).
Next, we used each CHTOP primer/probe set to test
for the relative degree of CpG methylation across a
series of non-islet tissues and different pancreatic cell
types. For comparison, we also tested the relative degree
of CpG methylation at the INS gene (CpG at − 69 bp
relative to the transcriptional start site) using our previ-
ously validated INS assay [6]. Figure 4 a shows relative
methylation of INS and CHTOP CpGs in non-pancreatic
Fig. 1 Methylation status of differentially methylated CpG sites identified by Infinium HumanMethylation 450 array. Infinium HumanMethylation
450 array was performed on bisulfite-treated DNA from 64 human islet samples and compared to data from 27 human non-islet tissues (control)
obtained from ENCODE DNA methylation datasets (GSE40699). Informatics analysis of these datasets identified 2534 hypomethylated CpG sites
and 3667 hypermethylated CpG sites in human islets vs. non-islet tissues (see Suppl. Table S4 for a full list of these CpGs). Shown are the box and
whisker plots of the data generated from the top 10 differentially methylated CpG sites. *P < 0.0001 for the comparison shown
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tissues. Whereas all tissues studied exhibited > 50%
methylation at the INS site (consistent with the absent
INS expression in these tissues), it is notable that
adipose tissue and skin exhibited only ~ 55–60% methy-
lation—a finding suggesting that excessive damage and/
or turnover of these tissues may increase circulating
unmethylated INS DNA levels. Similarly, for all CHTOP
sites studied, skeletal muscle, brain, and heart demon-
strated ≤ 50% methylation suggesting also that damage
and/or turnover of these tissues could increase circulat-
ing unmethylated CHTOP DNA levels. In pancreatic
tissue, INS exhibited hypomethylation in both β cells
and α cells, but not in whole pancreas (which is largely
comprised of acinar cells) (Fig. 4b); by contrast, all
CHTOP sites exhibited relative hypomethylation in β
cells, and to a lesser extent in α cells and whole pan-
creas. These pancreatic tissue patterns are unaltered by
cytokine treatment (Fig. 4b) or in the type 2 diabetic
state (Fig. 4c).
Because all CHTOP sites studied exhibited similar
overall characteristics across the tissues, we restricted
the remainder of our analyses to CHTOP-817, for
which we had the most detailed sensitivity and linearity
characteristics (Fig. 3). To evaluate if the utilization of
both the INS and CHTOP-817 assays together improves
the ability to predict the tissue origin of the circulating
DNA, we utilized a Naïve Bayes classifier, which is
known to perform well with small sample sizes and
fewer features [13]. The Naïve Bayes classifier uses
Bayes Theorem to predict the membership of a sample
Fig. 2 Validation of differentially methylated genes using DNA sequencing. DNA was isolated from Newport Green flow-sorted human β cells
(from N = 3 independent donors), EndoC-βH1 human fetal β cell-derived line (from N = 3 independent cultures), and 11 human control tissues
(each from a single donor). DNA sequencing was performed after bisulfite conversion on the top 5 differentially methylated genes identified by
the Infinium HumanMethylation 450 array. a Heatmap of the relative abundance of methylated (red) and hypomethylated (blue) CpG sites
indicated for intergenic, SPATS2, and PPP2R3A genomic locations. b Heatmap of the relative abundance of methylated (red) and hypomethylated
(blue) CpG sites indicated for the CHTOP gene
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treating each feature as an independent variable, in this
case to predict tissue type using single-feature models
with INS and CHTOP-817 alone, as well as a two-
feature model with both unmethylated INS and
CHTOP-817 (see the “Methods” section for details).
Four tissue type models were evaluated: (1) β cell, (2)
islet (which includes both α and β cells), (3) pancreas
(which includes islets and non-islet cells), and (4) β cell
vs. α cell. Table 1 shows the average classification ac-
curacy (%) based on 5-fold cross validation repeated
100 times using a Naïve Bayes classifier. In all cases,
accuracy is improved when considering both assays to-
gether, but 100% accuracy is achieved only for islets
(which includes both α and β cells).
Assessment of unmethylated and methylated CHTOP-817
and INS DNA in youth with T1D
To validate our assay in human subjects with known
islet cell death, we applied both the CHTOP-817 and
INS differentially methylated DNA assays to serum
from a cohort of subjects with new-onset T1D (within
48 h of diagnosis) and compared them to healthy
Fig. 3 Validation of linearity and sensitivity of dPCR assay for measurement of differential methylation of the CHTOP-817. Plasmid DNA or islet
DNA-spiked sera were subjected to droplet dPCR for differentially methylated CHTOP-817 at varying ratios or concentrations. a Representative 2-D
plots from droplet dPCR output of the gating strategy using the cloned unmethylated and methylated CHTOP gene plasmids. b Droplet dPCR
quantitation of mixed plasmid dilution of the cloned unmethylated and methylated CHTOP gene plasmids from a representative single
experiment (displayed as copies of DNA/microliter). c Droplet dPCR quantitation of unmethylated CHTOP-817 after serial dilution of human islet
DNA into serum from a healthy human donor (data shown are mean ± SEM from 3 independent dilution experiments from the same islet
donor). d Droplet dPCR quantitation of methylated CHTOP-817 after serial dilution of human islet DNA into serum from a healthy human donor
(data shown are mean ± SEM from 3 independent dilution experiments from the same islet donor). The insets in c and d show an expanded
view of the dilution curve at lower DNA concentrations
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control subjects. Relevant demographic and laboratory
information are presented in Table 2. As shown in
Fig. 5a–d, both unmethylated and methylated
CHTOP-817 and INS DNA were significantly higher
in subjects with new onset T1D compared to healthy
controls, a result consistent with our prior studies on
INS DNA [6]. Remarkably, when tested in first-degree
relatives (FDRs) of subjects with T1D who did not
have diabetes or evidence of islet autoimmunity (auto-
antibody negative), both unmethylated and methylated
CHTOP-817 and INS were also significantly increased
compared to unrelated healthy control subjects (Fig.
5a–d), a result suggesting that underlying genetic risk
may give rise to islet cell death.
Fig. 4 Relative abundance of differentially methylated CHTOP and INS DNA in human tissue samples by droplet dPCR. DNA from the indicated
human tissues was isolated, bisulfite treated, and differentially methylated CHTOP-817, − 800, − 824, and INS DNA levels were quantitated by
droplet dPCR. Data are displayed as a heatmap (blue = unmethylated, red = methylated). a Non-pancreatic tissues, each from a single donor. b
Flow-sorted β cells (N = 3 donors) treated with and without proinflammatory cytokines (IL-1β and IFN-γ), α cells (N = 3 donors) treated with and
without proinflammatory cytokines, and total pancreas (N = 6 donors). c Flow-sorted β cells (N = 3 donors) treated with and without
proinflammatory cytokines, α cells (N = 2 donors) treated with and without proinflammatory cytokines, and total pancreas (N = 3 donors) from
subjects with type 2 diabetes
Table 1 Average classification accuracy based on 100
repetitions of 5-fold cross validation of four tissue-type
classifications when using only unmethylated INS, only
unmethylated CHTOP-817, or both unmethylated INS + CHTOP-
817 together with a P < 10−30
INS CHTOP-817 INS + CHTOP-817
β cells vs. other tissues 80.6 86 88.8
Islet cells vs. other tissues 98.3 76.8 100
Pancreatic cells vs. other tissues 70.8 92.7 94.8
β cells vs. α cells vs. other tissues 86 68.7 92.7
Table 2 Demographic details of controls, youth with T1D, first-
degree relatives (FDR), and sepsis cohorts
Youth with T1D and first-degree relatives (FDRs)
Control FDR New-onset T1D P value
Total (% male) 10 (50) 23 (57) 43 (59)
Age (years) 11 ± 1.1 10 ± 0.4 7.4 ± 0.6 0.126
Sepsis cohorts
Control Sepsis P value
Total (% male) 10 (60) 10 (60)
Age (years) 14 ± 0.6 11 ± 1.4 0.98
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Assessment of unmethylated and methylated CHTOP-817
and INS DNA in obese youth
To determine if our assays could detect islet cell death
associated with insulin resistance, we measured differen-
tially methylated INS and CHTOP-817 DNA levels in co-
horts of lean and overweight/obese youth (see clinical
characteristics in Table 3). The overweight/obese youth
as a group showed significantly higher levels of both
unmethylated CHTOP-817 and INS; given that both
DNA species show hypomethylation in islet cells, and as-
suming that the elevated DNA signals are arising from
the same cell type, we interpret these data as suggesting
the occurrence of islet cell death in the overweight/obese
cohort of youth. Methylated INS DNA, which arises
from non-islet cell types, was also significantly elevated
in the overweight/lean cohort compared to lean control
youth, but no changes in methylated CHTOP-817 DNA
were observed between groups (Fig. 6a–d).
To assess if any of these differences were driven by dif-
ferences in glycemic control, we stratified our cohorts by
glycemic control as follows: lean controls with normal
glucose tolerance (NGT), overweight/obese with normal
glucose tolerance (OB-NGT), overweight/obese with im-
paired glucose tolerance (IGT), and overweight/obese
with T2D with and without evidence of autoantibodies
(T2D, AAb+, and T2D-AAb−, respectively). As shown in
Fig. 6e–h, there were no statistically significant differ-
ences in unmethylated CHTOP-817 and unmethylated
Fig. 5 Circulating differentially methylated CHTOP-817 and INS DNA levels in control, new-onset T1D, and autoantibody-negative first-degree
relatives (FDRs) of individuals with T1D. DNA was isolated from serum, bisulfite-converted, and differentially methylated CHTOP-817 and INS levels
were analyzed by droplet dPCR. a Log of unmethylated CHTOP-817 DNA levels; b log of methylated CHTOP-817 DNA levels; c log of
unmethylated INS DNA levels; d log of methylated INS DNA levels. Data are presented as mean ± SEM and each symbol represents an individual
donor. *P < 0.05 for the comparisons indicated
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INS DNA among these cross-sectional cohorts, suggest-
ing that the overall increases in unmethylated DNA spe-
cies in the overweight/obese youth reflect a difference
largely driven by weight. Methylated CHTOP-817 DNA
was similar across cohorts (Fig. 6f); however, methylated
INS DNA was significantly elevated in obese youth with
normal glucose tolerance (OB-NGT), IGT, and T2D-
AAb+ compared to healthy lean controls (Fig. 6h).
Elevations in methylated INS and CHTOP-817 DNA may
be associated with systemic inflammatory states
The elevation in methylated INS in youth with obesity is
reminiscent of the elevations in methylated INS we re-
ported in youth with new-onset T1D [6]. In this regard,
studies in humans suggest that total cell-free DNA levels
increase with severity of systemic inflammation/illness in
youth [14]. We therefore hypothesized that the elevation
in methylated INS and CHTOP-817 in our populations
might reflect concurrent systemic inflammation related
to the underlying T1D or overweight/obesity. To test
this hypothesis, we next applied our assays to sera from
youth with severe illness (sepsis requiring intensive care
unit-level care) and compared them to age- and sex-
matched healthy controls (see Table 2). As shown in Fig.
7a–d, compared to controls, subjects with sepsis
exhibited elevations in methylated INS and CHTOP-817
DNA levels (Fig. 7b, d) but not the corresponding
unmethylated DNA levels (Fig. 7a, c).
Discussion
Measurement of circulating differentially-ethylated
DNA species has been gaining attention as a minim-
ally invasive biomarker of β cell death that may be
used to distinguish individuals with impending and
new-onset T1D [6–8, 15–17]. However, owing to the
variability of INS methylation among various non-β
cell types, it cannot be definitively concluded that the
signal identified emanates from the islets alone. It is
likely that multiple biomarkers will be required to un-
ambiguously detect islet damage. Our study represents
a step in this direction. Four key findings emanate
from our study: (a) neither differentially methylated
CHTOP nor INS exhibits specificity for the β cell
within the islet, as α cells also exhibit nearly the same
degree of unmethylation at these (and by inference
other) genes, (b) the combination of unmethylated
CHTOP-817 and INS DNA levels provides greater
confidence that signals are originating from islet cells,
(c) autoantibody-negative FDRs of individuals with
T1D exhibit a circulating differentially methylated
DNA signature similar to individuals with T1D, and
(d) youth with overweight/obesity, as a group, exhibit
elevated markers consistent with islet cell death and
inflammation.
Using an unbiased approach by extracting data from
our present and previous studies using the Infinium®
450 K array, we identified CHTOP as a gene that was
highly differentially methylated in primary human islets.
We performed DNA sequencing in non-islet tissues, pri-
mary human β cells and α cells, and the validated human
β cell line EndoC-βH1. Our finding that both CHTOP
and INS were largely unmethylated in both β cells and α
cells is consistent with the common embryonic origin of
both cell types, and is further consistent with studies
showing that hypomethylation of genes (especially in
promoter regions) is a shared feature of α and β cells
[18]. We therefore suggest that assays employing differ-
ently methylated genes likely report broadly on islet cell
death, rather than β cell death specifically. Another
important finding in our studies was that CHTOP was
Table 3 Clinical and anthropometric characteristics of youth obesity and T2D cohorts





Total (% male) 32 (56) 31 (35) 31 (35) 34 (47) 22 (45)
Age, years 13 ± 0.2 14 ± 0.3 15 ± 0.4 15 ± 0.3 14 ± 0.5 < 0.001
BMI, Z score (ZS) -0.14 ± 0.15 2.21 ± 0.10 2.33 ± 0.06 2.39 ± 0.05 1.90 ± 0.12 < 0.001
HbA1c (%) 5.3 ± 0.1 5.4 ± 0.1 5.4 ± 0.1 6.6 ± 0.1 6.3 ± 0.2 < 0.001
Fasting glucose, mg/dL 95.3 ± 3.5 90.8 ± 3.5 92.5 ± 3.5 115.1 ± 3.4 129.1 ± 5.0 < 0.001
2-h OGTT glucose, mg/dL N/A 111.4 ± 10.5 158.8 ± 8.4 197.5 ± 8.1 299.1 ± 12.1 < 0.001
Treatment modality N (%)
Lifestyle 7 (21) 2 (13)
Insulin 4 (12) 3 (19)
Metformin 16 (47) 2 (13)
Insulin and metformin 7 (21) 9 (56)
*P values indicate significance across all cohorts by one-way ANOVA
OB-NGT obese normal glucose tolerance, IGT impaired glucose tolerance, AAb− autoantibody negative, AAb+ autoantibody positive
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found to be hypomethylated in primary human β cells,
but not in the EndoC-βH1 cells, a human embryo-
derived β cell line [11]. This result suggests that while
this cell line has proven useful in interrogating β cell
biology, its epigenetic landscape may not be reflective of
mature β cells.
The interpretation of results of differentially methyl-
ated DNA assays most often requires context with re-
gard to the populations being assessed, since they may
not be sufficiently specific for β cells to exclude other
damaged or dying cell types. In this respect, our results
show that other non-islet cell types exhibit at least 50%
Fig. 6 Circulating CHTOP-817 and INS DNA levels in youth with obesity with or without T2D. DNA was isolated from serum, bisulfite-converted,
and differentially methylated CHTOP-817 and INS levels were measured by droplet dPCR. a Log of circulating unmethylated CHTOP DNA levels in
lean and obese youth; b log of circulating methylated CHTOP DNA levels in lean and obese youth; c log of circulating unmethylated INS DNA
levels in lean and obese youth; d log of circulating methylated INS DNA levels in lean and obese youth; e–h log of circulating unmethylated
CHTOP-817 (e) and INS (g) and methylated CHTOP-817 (f) and INS (h) DNA levels in lean youth with normal glucose tolerance (NGT) and youth
with obesity and normal glucose tolerance (OB-NGT), obesity and impaired glucose tolerance (IGT), and clinician-diagnosed obesity with T2D
without (T2D-AAb−) and with (T2D-AAb+) autoantibodies. Data are presented as mean ± SEM. *P < 0.05 for the comparisons indicated
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hypomethylation of the CpG sites in the CHTOP and
INS genes (brain, skeletal muscle, and heart for CHTOP,
and adipose and skin for INS). Others have similarly re-
ported varying degrees of hypomethylation of INS across
different cell types [7]. In the setting of new/recent-onset
T1D and the immediate post-islet transplant period, the
suggestion of β cell death is unlikely to be complicated by
death of the other cell types studied here, and therefore
the interpretation of prior INS assays under these condi-
tions has been relatively straightforward [5, 6, 8, 19, 20].
By contrast, under more ambiguous circumstances, such
as in individuals at risk for developing T1D or T2D, where
the occurrence and timing of β cell death has yet to be de-
fined, these assays may prove more challenging to inter-
pret. For example, we observed that both circulating
unmethylated CHTOP-817 and INS were elevated in sub-
jects with new-onset T1D—a finding consistent with the
plausibility of active β cell death in these individuals. How-
ever, the similar finding of elevated circulating unmethy-
lated CHTOP-817 and INS in autoantibody-negative FDRs
of individuals with T1D poses an interpretative challenge.
Studies of autoantibody-negative relatives of T1D subjects
have shown systemic signatures of prevailing innate im-
munity [21], and more recently it was demonstrated that
autoantibody-negative FDRs of individuals with T1D ex-
hibit reduced pancreatic volume [22]. Moreover, a review
of published studies of healthy relatives of individuals with
T1D is suggestive of prevailing β cell dysfunction in this
group [23]. Thus, our data on FDRs add to the existing lit-
erature of abnormalities in these subjects: the combination
Fig. 7 Circulating CHTOP-817 and INS DNA levels in youth with sepsis. DNA was isolated from serum, bisulfite-converted, and differentially
methylated CHTOP-817 and INS DNA levels were measured by droplet dPCR. a Log of unmethylated CHTOP-817 DNA levels; b log of methylated
CHTOP-817 DNA levels; b log of unmethylated INS DNA levels; d log of methylated INS DNA levels. Data are presented as mean ± SEM. *P < 0.05
for the comparisons indicated
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of elevated circulating unmethylated CHTOP-817 and
unmethylated INS in these subjects seemingly excludes
death of non-islet cell types (since CHTOP and INS have
non-overlapping patterns of unmethylation outside of the
islet, Fig. 4) and raises the specter of islet cell death/turn-
over in this group.
In T2D, the primary etiology of reduced insulin secre-
tion remains unclear. Autopsy studies have demon-
strated increases in β cell mass in adults with obesity
and prediabetes compared to controls, and lower β cell
mass in individuals with frank T2D compared to con-
trols [24–26]. In obese youth, comprehensive autopsy
data are not available, but functional data suggest a
worsening of β cell function with increasing dysglycemia
[27]. The loss in functional β cell mass in T2D has been
attributed variably to β cell apoptosis and/or dedifferen-
tiation [24, 25, 28, 29], but definitive evidence for either
is lacking. We discovered that unmethylated INS and
CHTOP-817 were significantly elevated in obese youth
compared to lean controls, but these increases were lost
when the groups were stratified by glycemia (noting that
statistical power decreased by the stratification). Given
that all individuals are either obese or overweight, it is
possible that the unmethylated INS signal might be aris-
ing from adipocyte turnover; however, the elevations in
unmethylated CHTOP-817, assuming that they are aris-
ing from the same cell type, likely point to an islet cell
origin. In a prior study using high-fat diet feeding in
mice, we observed that overweight/obese mice exhibit
periodic increases in unmethylated INS DNA, and that
these elevations correlated with increases in β cell death,
as verified by immunostaining of pancreas sections from
these animals [30]. These data suggest that the elevated
unmethylated INS and CHTOP-817 signal in our cohort
of overweight/obese youth might be arising from death
of islet cells, recognizing that our assay cannot defini-
tively conclude the specific islet cell type giving rise to
this signal.
We showed previously that methylated INS was ele-
vated in subjects with new-onset T1D; because methyl-
ated INS (and CHTOP-817) have the potential to arise
from any cell type, we interpreted these findings as sug-
gestive of turnover of cell types that reflect the general
inflammatory state seen in T1D [6]. Here, we demon-
strate that youth with severe systemic inflammation/ill-
ness (sepsis) exhibit elevated methylated CHTOP-817
and INS, without changes in corresponding unmethy-
lated DNA levels. Our data are consistent with prior re-
ports that suggest that systemic illnesses lead to
elevations in circulating cell-free DNA levels [14].
Conclusions
In closing, some caveats to our study should be noted.
First, our studies in humans utilized cross-sectional
cohorts, and we cannot comment on the occurrence or
the timing of islet cell death following initial islet assault
during the progression from obesity to T2D or from
antibody-negative FDR to T1D. Given the short (~ 90
min) half-life of DNA in the circulation [15], if β cell
death was episodic during disease progression in
humans (as we observed previously in mice [30]), signals
corresponding to cell death could be missed depending
on the timing of sampling. Additional studies measuring
differentially methylated INS and CHTOP from longitu-
dinal cohorts are needed to resolve this issue. Second,
neither our unmethylated CHTOP nor INS assays can
reliably distinguish β cell death vs. death of other islet
cell types; this caveat may well apply to all cell-free DNA
assays developed to date. Thus, it is imperative that all
cell-free DNA assays rigorously test their specificity for
different human tissues (as we have done here). Taken
together, our data suggest that genes not known to be
exclusively expressed in islets may still serve as potential
biomarkers of islet cell death. The combination of mul-
tiple such biomarkers may help to increase specificity of
their correlation to β cell/islet cell death and may pro-
vide insight into the cellular pathophysiology of diabetes.
Methods
Isolation of primary human β cells
Dissociation of human islets was achieved by incubation
with accutase (Millipore) supplemented with 5U/ml of
DNAse 1 at 37 °C for 10–15min. The dissociated cells were
washed with 1% BSA in PBS and cultured in islet standard
medium (Prodo labs) and followed by Newport Green la-
beling [31]. β cells and non-β cells were sorted by positive
or negative Newport Green staining (respectively) using a
BD FACSAria cell sorter (BD Biosciences). The quality of
the sorted cells was further confirmed by immunofluores-
cence staining of insulin (guinea pig anti-insulin, Dako) and
glucagon (mouse anti-glucagon, Abcam).
Methylation-specific DNA sequencing
We performed a methylation specific Infinium Human-
Methylation 450 array (Illumina) of 64 human islet prep-
arations (see Suppl. Table S1 for sample details) and
compared them with 27 human tissues/cell lines; the
control data were retrieved from the Encyclopedia of
DNA Elements (ENCODE) [32] DNA methylation
database using GEO repository GSE40699 (see Suppl.
Table S2 for sample details). The Infinium data (human
islets and ENCODE controls) were filtered by removing
low-quality data using a detection P value threshold of
0.05. Cross-reactive probes (those that co-hybridize at
different genomic locations) and probes containing SNPs
were filtered out using the extended annotation as
previously described [33]. Beta values were computed
using the formula Beta value = M/(U + M) where M and
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U are the raw “methylated” and “unmethylated” signals,
respectively.
For the human tissues/cell control data, the first selec-
tion of markers was performed by detecting CpG sites
showing a significant differential methylation between
the two groups (human islets vs non-islet tissues). CpGs
with an absolute delta beta > 0.5 (i.e., difference between
average methylation levels in each group) and a cor-
rected P value < 0.001 computed using Mann–Whitney
U test followed by Benjamini-Hochberg multi-testing
correction were selected. CpGs displaying a delta beta >
0.5 (i.e., methylation difference higher than 50% between
the islet group and the control group) were considered
as hypermethylated, while the CpGs displaying a delta
beta ≤ 0.5 where considered as hypomethylated (see
Suppl. Table S4 for a full list of all hyper- and hypo-
methylated CpGs, their respective delta beta values and
P values).
For experimental confirmation of differentially methyl-
ated CpGs, DNA was isolated from sorted human β
cells, EndoC βH1 cells, and human tissues (brain, heart,
lung, thyroid, spleen, intestine, skin, skeletal muscle, adi-
pose, pituitary, pancreas, and liver) following manufac-
turer’s protocol (GenElute™ Mammalian Genomic DNA
Miniprep kits, Sigma). Following isolation, DNA was bi-
sulfite treated using EZ DNA Methylation-Lightning Kit
(Zymo Research), and PCR was performed using primers
specifically designed to amplify bisulfite-converted DNA
(Suppl. Table S3). Primers were designed using the Mac-
Vector® software (MacVector, Inc.). PCR products were
purified using a QIAquick PCR purification kit (Qiagen)
and DNA was quantified using a Qubit dsDNA assay kit
(Invitrogen). Equal amounts of DNA were used for li-
brary preparation. Fully methylated or unmethylated
synthetic DNA was used as a positive control to calcu-
late the degree of methylation. Methylation-specific
DNA sequencing was performed using an Ion Proton
System (LifeTechnologies).
Plasmid synthesis
Unmethylated and methylated CHTOP and INS-contain-
ing plasmids were constructed from PCR-generated
products using a TOPOTM TA Cloning kit (Thermo
Fisher) DNA from β cells and non-β cells. The TOPO-
DNA constructs were transformed into E.coli and
cultured overnight on LB plates containing ampicillin.
Single colonies were handpicked for miniprep cultures
and DNA from bacteria was isolated using an QIAprep
Spin Miniprep kit (Qiagen). The plasmid sequence was
confirmed by DNA sequencing (Sanger) using M13R
primers.
Methylation specific multiplex droplet dPCR assay
TaqMan® probes were designed for the interrogation of
differential methylation pattern at CpG sites chr1,
153610817; chr1, 153610800; and chr1, 153610824 of
the CHTOP gene by multiplex droplet dPCR. Primers
and probes were as follows: chr1, 153610817: forward,
5′-TTTGGAGTTTTTGGTTTAGTAAGTTATGAAAA
TGTT; reverse, 5′-CATCTACTAAACCAATCTTCTA
TTTCTAACACTAACTAA; VIC probe, 5′-AAACCCG
AATATTCAC; FAM probe, 5′-AAACCCAAATATTC
AC. chr1, 153610800: forward, 5′-TTTGGAGTTTTTG
GTTTAGTAAGTTATGAAAATGTT; reverse, 5′-CAT
CTACTAAACCAATCTTCTATTTCTAACACTAACT
AA; VIC probe, 5′-AATATGTTGAAGAATAAATAGT
CGA; FAM probe, 5′-AATATGTTGAAGAATAAATA
GTTGA. chr1, 153610824: forward, 5′-TTTGGAGTTT
TTGGTTTAGTAAGTTATGAAAATGTT; reverse, 5′-
CCATCTACTAAACCAATCTTCTATTTCTAACACT;
VIC probe, 5′-ACTACATCGAAACCC; FAM probe, 5′-
ACTACATCAAAACCC. Primers and probes for the
INS gene (site—69 bp relative to the transcriptional start
site) were described previously [6, 9]. Assay linearity was
determined by serial dilution of unmethylated and
methylated plasmids. For the calculation of relative
methylation in heatmaps, the ratio of abundance of the
unmethylated to methylated DNA fragments was ob-
tained by dPCR and assigned a color along a gradient
(blue = hypomethylated to red = hypermethylated) using
the GraphPad Prism 7.0c software (GraphPad).
Human subjects
The samples in the T1D/first-degree relative (FDR) co-
hort are from the DiMelli and TeenDiab studies. The
DiMelli study included subjects with incident T1D in
childhood in Bavaria, Germany [34]. Samples from 43
subjects (mean age 7.4 years) who were positive for one
or more islet autoantibodies were selected for the study.
Samples from 23 islet autoantibody-negative first-degree
relatives (FDRs) (mean age 10 years) of individuals with
T1D were obtained from the TeenDiab Study [35]. All
samples were collected with informed consent by the pa-
tients or their legal parents/guardians. The DiMelli study
was approved by the Bayerische Landesaerztekammer
and the TeenDiab study by the Ludwig-Maximilians
University.
Frozen fasting serum samples from 150 youth, ages 10
to < 20 years old, who participated in NIH-funded K24
grant of “Childhood Insulin Resistance” were used for
the obesity/overweight/T2D cohort. Data unrelated to
the present project have been published [27, 36–40].
Participants were recruited through newspaper adver-
tisements, flyers posted in the medical campus, city bus
routes, and the outpatient clinics in the Weight Manage-
ment and Wellness Center and the Division of Pediatric
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Endocrinology at the Children’s Hospital of Pittsburgh.
The study was approved by the institutional review
board of the University of Pittsburgh and written in-
formed parental consent and child assent were obtained
from all participants before any research participation in
accordance with the ethical guidelines of Children’s Hos-
pital of Pittsburgh. A 2-h OGTT was performed in obese
participants as described before [36]. GAD 65 kDa
autoantibody and insulinoma-associated protein 2
autoantibody (IA2) were measured using the NIDDK
standardized assay protocol as described before [40].
Participants with diabetes were on either lifestyle only,
or metformin or metformin plus insulin (Table 3).
Samples from control youth and youth with sepsis
were obtained after informed consent and approved
through the Indiana University Institutional Review
Board.
DNA isolation and bisulfite conversion
DNA from tissue and cell samples was isolated using
GenElute Mammalian Genomic DNA Miniprep Kit
(Sigma-Aldrich). DNA from serum was isolated from 50
μl of serum samples spiked in with 5 μg carrier DNA
(poly-A) using QIAamp DNA Blood Mini Kit (Qiagen).
DNA recovery from serum samples (of the poly-A car-
rier) was quantified using a nanophotometer (Implen).
All samples showed ≥ 85% recovery of DNA following
isolation. DNA bisulfite conversion was carried out using
EZ DNA Methylation-Lightning Kit (Zymo Research),
and conversion was verified using a pre- and post-
conversion sample in the droplet dPCR.
Statistical analysis
All data are presented as mean ± SEM. For analysis of
methylated and unmethylated INS DNA levels, a
Kruskal-Wallis (non-parametric) test was employed
followed by a Dunnett’s posttest (to compare values to
healthy controls). GraphPad Prism Version 7.0c (Graph-
Pad Software) was used for statistical analyses of sample
data. Statistical significance was assumed at P < 0.05.
To evaluate if the utilization of INS and CHTOP assays
together improves the ability to predict the tissue type,
we utilized a Naïve Bayes classifier to predict tissue type
specificity using single-feature models with INS and
CHTOP alone, as well as a two-feature model with INS
and CHTOP. Five-fold cross validation (CV) was pre-
formed and each sample was classified based on the pos-
terior probability at a threshold of 0.5. Once all samples
were classified, the classification accuracy was computed
as the proportion correctly classified. Four tissue type
specificity models were evaluated: (1) beta cell specific;
(2) islet cell specific, which includes alpha and beta cells;
(3) pancreas specific, which included islet and non-islet
cells; and (4) islet cell-type (β cells vs. α cells) specific.
To assure that the results were not biased by the ran-
dom CV selection, the 5-fold CV process was performed
100 times. The same CV datasets were used for the sin-
gle and double models. A non-parametric test was uti-
lized to compare the accuracy of the INS, CHTOP, and
BOTH assay evaluation. Thus, the 100 observed classifi-
cation accuracy estimates were compared across assays
using a Friedman test to account for the repeated mea-
sures in a non-parametric test. A subsequent Tukey-
Cramer post hoc test was used to determine the statis-
tical significance between the three comparisons.
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